Hinge Health, Inc. Class A (HNGE) AI Stock Analysis

• Market Cap: $4.19B
• Dividend Yield: N/A
• Average Volume (3M): 995.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.37
• Revenue Growth: 50.67%
• EPS Growth: -578.03%
• Country: US
• Employees: 1,514
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.42
• Shares Outstanding: 27,223,448
• 10 Day Avg. Volume: 978,065
• 30 Day Avg. Volume: 995,219
• PEG Ratio: 2.75
• Price to Book (P/B): 7.03
• Price to Sales (P/S): 7.51
• P/FCF Ratio: 64.79
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $63.58
• Price Target Upside: 40.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: $49.00 ▲(7.95% Upside)

Hinge Health, Inc. shows strong financial performance with impressive revenue growth and cash flow improvements. The earnings call further supports a positive outlook with enhanced operational efficiency and AI-driven innovations. However, technical indicators suggest a bearish trend, and the negative P/E ratio reflects ongoing profitability challenges. Concerns about a seasonal slowdown and potential impacts from external factors also weigh on the overall score.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Hinge Health's services and successful market penetration, supporting long-term business expansion.

Operational Efficiency

Improved operational efficiency and higher gross margins suggest effective cost management, enhancing profitability prospects over time.

AI and Automation Initiatives

AI-driven innovations can enhance service delivery and operational efficiency, positioning Hinge Health as a leader in digital health solutions.

Negative Factors

Profitability Challenges

Ongoing profitability challenges could hinder long-term financial stability and investor confidence, requiring strategic focus on cost control and revenue growth.

Seasonal Slowdown

Anticipated seasonal slowdown may impact short-term financial performance, necessitating strategies to mitigate cyclical revenue fluctuations.

Impact of Federal Government Shutdown

Potential disruptions from a federal government shutdown could affect operations and revenue, highlighting the need for contingency planning.

Hinge Health, Inc. Class A Business Overview & Revenue Model

Company Description

Hinge Health, Inc. develops health care software for joint and muscle health. The company designs its platform to address a musculoskeletal care, acute injury, chronic pain, and post-surgical rehabilitation. It also provides various administrative and operations support services. The company was founded in 2012 and is headquartered in San Francisco, California.

How the Company Makes Money

Hinge Health makes money primarily through partnerships with employers and health insurance plans. The company offers its digital MSK care platform as a subscription-based service, where organizations pay for access to its comprehensive suite of tools and services designed to manage and reduce musculoskeletal issues among their members or employees. Key revenue streams include subscription fees from these corporate clients, who integrate Hinge Health's solutions into their employee health benefits packages. Additionally, Hinge Health may engage in significant partnerships with healthcare providers and systems to extend its reach and enhance its service offerings, thereby contributing to its earnings.

Hinge Health, Inc. Class A Financial Statement Overview

Summary

Hinge Health, Inc. shows strong revenue growth and effective cost control with a high gross profit margin. The balance sheet is stable with low leverage, but profitability remains a challenge. Cash flow improvements are promising, but sustained positive net income will be crucial for long-term success.

Income Statement

Hinge Health, Inc. has shown a significant improvement in revenue, with a growth rate of 33.33% over the past year. The gross profit margin is strong at 76.80%, indicating effective cost management. However, the company remains unprofitable with a net profit margin of -3.06% and negative EBIT and EBITDA margins, reflecting continued operational challenges.

Balance Sheet

The balance sheet is solid with a low debt-to-equity ratio of 0.03, suggesting low leverage and financial stability. The equity ratio is 61.91%, indicating a strong capital structure. However, the return on equity is negative at -2.86% due to ongoing losses, which is a concern for investors seeking profitability.

Cash Flow

Cash flow has improved markedly with a free cash flow growth rate of 165.99%. The operating cash flow to net income ratio is positive at 4.11, indicating efficient cash generation despite net losses. The free cash flow to net income ratio is also positive at 3.79, reflecting strong cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023
Income Statement
Total Revenue	417.13M	390.40M	292.73M
Gross Profit	324.19M	299.90M	194.18M
EBITDA	-566.29M	-25.96M	-124.89M
Net Income	-560.36M	-11.93M	-108.14M
Balance Sheet
Total Assets	769.80M	673.26M	622.53M
Cash, Cash Equivalents and Short-Term Investments	480.03M	466.57M	423.36M
Total Debt	9.03M	11.07M	15.73M
Total Liabilities	361.93M	256.56M	195.25M
Stockholders Equity	208.00M	416.70M	427.28M
Cash Flow
Free Cash Flow	103.85M	45.23M	-68.52M
Operating Cash Flow	107.55M	49.00M	-63.91M
Investing Cash Flow	-76.07M	18.31M	1.50M
Financing Cash Flow	-70.92M	-2.20M	-3.00M

Hinge Health, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HNGE	64 Neutral	$4.19B	―	―	―	50.67%	-578.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TIVC	43 Neutral	$3.92M	-0.20	-160.96%	―	-58.49%	84.67%
MSPR	41 Neutral	$996.00K	―	-2151.29%	―	76.98%	-52.89%
HSCS	38 Underperform	$7.49M	―	-193.24%	―	-66.40%	65.99%
BJDX	29 Underperform	$3.25M	-0.05	-96.69%	―	―	98.25%

Hinge Health, Inc. Class A Corporate Events

Hinge Health’s Earnings Call: Strong Growth Amid Challenges

Hinge Health, Inc. Class A’s recent earnings call exuded optimism, underscored by substantial revenue growth, enhanced operational efficiency, and successful AI initiatives, all pointing to robust business momentum. Despite these positive developments, the company acknowledged potential challenges, including a seasonal slowdown in Q4 and uncertainties stemming from a federal government shutdown.

Hinge Health Reports Strong Q3 2025 Financial Results

Hinge Health, Inc., headquartered in San Francisco, California, is a healthcare company specializing in the automation of care delivery for musculoskeletal conditions through an AI-powered platform. The company leverages wearable devices and expert clinicians to provide personalized, evidence-based care aimed at improving patient outcomes and reducing costs for clients.

Hinge Health Reports Strong Q3 2025 Financial Results

On November 4, 2025, Hinge Health announced its financial results for the third quarter of 2025, highlighting a 53% increase in revenue year-over-year to $154.2 million and a significant rise in free cash flow. The company reported surpassing 1.5 million lifetime members and a 25% increase in clients, indicating strong growth and market expansion. Despite a GAAP loss from operations, the non-GAAP income from operations showed a substantial improvement. The company also provided an optimistic financial outlook for the fourth quarter and full year of 2025, projecting continued revenue growth and increased non-GAAP income from operations.

The most recent analyst rating on (HNGE) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Hinge Health, Inc. Class A stock, see the HNGE Stock Forecast page.

Hinge Health Announces Early Share Lock-Up Release

Hinge Health, Inc. recently completed its initial public offering (IPO) of Class A common stock, during which directors, executive officers, and other key stakeholders entered into lock-up agreements restricting the sale of shares for up to 180 days post-IPO. On August 6, 2025, the company met conditions allowing for an early release of 1.66 million shares from these restrictions, enabling their sale starting August 19, 2025, while the remaining shares remain under lock-up.

The most recent analyst rating on (HNGE) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Hinge Health, Inc. Class A stock, see the HNGE Stock Forecast page.

Hinge Health Reports Strong Q2 2025 Growth

Hinge Health, Inc. is a San Francisco-based company specializing in the delivery of healthcare solutions for musculoskeletal conditions through an AI-powered platform, combining wearable devices and expert clinician access to provide personalized care.